Kimberly-Clark agreed to acquire Kenvue in a cash-and-stock deal valuing the Johnson & Johnson spin-off at about $48.7 billion in enterprise value. Kenvue holders are set to receive $3.50 in cash plus 0.14625 Kimberly-Clark shares per Kenvue share, equal to $21.01 per share based on October 31 pricing, a 46% premium to Kenvue’s prior close.… The post Kimberly-Clark’s $48.7B Kenvue bet is to pay a premium amid Tylenol noise appeared first on Drug Discovery and Development.| Drug Discovery and Development
Ken Paxton, the Republican attorney general of Texas, sued Kenvue, the manufacturer of Tylenol, on Tuesday, for “deceptively marketing Tylenol to pregnant mothers despite knowing that early exposure to acetaminophen leads to a significantly increased risk of autism and other disorders,” according to the press release. J&J illegally offloaded liability, Paxton claims Paxton also claimed… The post Texas sues Kenvue claiming it hid link between Tylenol and autism appeared first on Drug D...| Drug Discovery and Development